Case series reveals an indolent clinical course and distinct epigenetic profile in GAB1::ABL1 spindle cell tumors, suggesting potential susceptibility to targeted kinase inhibitors.
Mesenchymal neoplasms driven by protein kinases represent an increasing group with a broad clinicopathologic and genetic spectrum. Recently, tumors harboring a GAB1::ABL1 fusion have been reported, resulting in constitutive activation of the non-receptor tyrosine kinase ABL1. We describe six cases (one previously reported) investigated by fusion gene analysis and DNA-methylation profiling. Tumors were from three males and three females aged 7–71 years and arose in the neck, axilla, lower back, thigh, and digits. Lesions were excised. Available follow-up was uneventful. Neoplasms were circumscribed but unencapsulated, with infiltration of the surrounding tissue, and characterized by haphazardly arranged monomorphous spindle cells. There was a fibromyxoid stroma and staghorn-like vessels were present. Immunohistochemically, expression of CD34 (3/6), S100 (1/6), EMA (2/6), and GLUT1 (3/3) was observed. All cases harbored a GAB1::ABL1 fusion. RNA expression profile (n = 2) showed high-confidence similarity to dermatofibrosarcoma protuberans (DFSP). DNA-methylation profiling demonstrated that all cases clustered together in close proximity to DFSP. Application of the latest Heidelberg methylation sarcoma classifier did not confidentially classify these neoplasms. However, four showed low-confidence matches to NTRK-rearranged spindle cell neoplasms. GAB1::ABL1 spindle cell neoplasms represent a distinct member of the family of kinase-driven mesenchymal tumors with an indolent clinical course, while the activating ABL1 fusion raises the possibility of targeted therapy in selected cases.
No takes yet. Share an insight, caveat, or question.
Hiemcke‐Jiwa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: